Ian Lentnek, MD
Cardiovascular Disease · Valhalla, NYNPI 1104093780
Payments from drug & device makers
What this record shows
This record is dominated by other: $270,058 of the $270,827 with a category attached, or 99.7%. Edwards Lifesciences accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $45,138 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$270K
- AstraZeneca$601
- Boston Scientific$169
What the payments were for
- Travel & lodging$4860%
- Food & beverage$2840%
- Other$270,058100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 2 | $270,058 |
| AstraZeneca | 3 | $601 |
| Boston Scientific | 1 | $169 |
How this compares
$270,827 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 165 | $834 |
| Metoprolol Tartrate | 120 | $668 |
| Atorvastatin Calcium | 97 | $632 |
| Lisinopril | 153 | $570 |
| Benazepril Hcl | 13 | $342 |
| Losartan Potassium | 45 | $315 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 14 | $291 |
| Hydrochlorothiazide | 78 | $264 |
| Nifedipine ErNifedipine | 34 | $257 |
| Doxazosin Mesylate | 17 | $129 |
| Amiloride Hcl | 13 | $119 |
| Metoprolol Succinate | 20 | $115 |
| Atenolol | 37 | $101 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 26 | $64 |
| Carvedilol | 24 | $60 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Valhalla
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.